Lipocine (NASDAQ:LPCN) Earns Hold Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Lipocine (NASDAQ:LPCN) in a report published on Saturday morning. The brokerage issued a hold rating on the specialty pharmaceutical company’s stock.

Lipocine Price Performance

Shares of Lipocine stock opened at $4.69 on Friday. The company’s fifty day moving average price is $4.82 and its two-hundred day moving average price is $4.89. Lipocine has a 52-week low of $3.20 and a 52-week high of $11.79. The firm has a market capitalization of $25.09 million, a PE ratio of -6.17 and a beta of 1.23.

Lipocine (NASDAQ:LPCN) last announced its earnings results on Thursday, November 7th. The specialty pharmaceutical company reported ($0.44) earnings per share for the quarter. Analysts predict that Lipocine will post -0.78 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Lipocine stock. Dimensional Fund Advisors LP acquired a new stake in Lipocine Inc. (NASDAQ:LPCN) during the 2nd quarter, according to its most recent disclosure with the SEC. The fund acquired 11,870 shares of the specialty pharmaceutical company’s stock, valued at approximately $98,000. Dimensional Fund Advisors LP owned approximately 0.22% of Lipocine at the end of the most recent quarter. 9.11% of the stock is owned by institutional investors and hedge funds.

About Lipocine

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.